Key Takeaways
- Sequential revenue surge, driven by agro: Revenue hit ₹47.1 crore, up 45% QoQ and 86% YoY, powered by the commercialization of two key agro intermediates, including a photochlorination-based product.
- Dahej plant handover unlocks the next leg: The new block was handed over to production on the day of the call, with commercial production expected in the first week of March, directly addressing infrastructure bottlenecks that have capped volume and margins.
- Semiconductor entry turns real: The company received its first plant-scale production order for three batches at ton scale, moving from pilot approvals to commercial reality, though full commercialization is still targeted for around 2028.
- Margin recovery thesis is set, not proven: Management sees a pricing bottom and expects the new plant to improve cost leverage, but underutilization costs at Dahej are a current drag and the recovery timeline depends on a smooth ramp-up.
- What to watch next quarter: The pace of commercial production from the new Dahej block, the conversion of delayed electrolyte salt shipments into recognized revenue, and any sustained uptick in pricing.
Revenue Performance & Drivers
- Agro intermediates lead the quarter: Revenue of ₹47.1 crore represented 45% sequential and 86% YoY growth, driven by the commercialization of two key agro intermediates, one of which uses photochlorination technology.
- Photochlorination execution was solid: Orders for the quarter were executed successfully, though delayed by 2-3 weeks; the chemistry and process worked well, and repeat orders have already been received for the April-June quarter.
- Electrolyte salts revenue slipped into Q4: Internal shipments from the destination port to customers were delayed, so sales did not reflect in Q3; from January, calendar year 2026 is expected to show 7-8% revenue from this category.
- SDA decline is a timing issue, not a demand signal: The 10% QoQ decline reflects the campaign-based nature of customer demand, where one quarter can have zero demand and another hundreds of tons; raw material pricing has remained stable for the last two quarters.
- Pricing has found a floor: Prices are trying to scale up but not sustaining, though they are not falling below current levels; management believes the bottom has been found.
Chintan Shah: "That is one, if someone can answer that question, because this is what we have been -- see, I told just a couple of questions back that prices are trying to scale up, but not sustain and again fall back. But the good part is, at least, they are not falling down below the current level. So that's a good part."
Dahej Plant & Capacity Expansion
- New block handed over on call day: The engineering team handed over the INR100 crores capex block at Dahej to the production team on 21 January 2026; water trials and leakage tests have begun, chemical trials started 1st February, and validation trials from 16th February, with commercial production expected in the first week of March.
- The block solves a structural bottleneck: The new infrastructure addresses missing capabilities in the production system, specifically recoveries, byproduct conversion, and solvent reuse, which have limited cost leverage and volume scaling.
- 70% of recent capex went to utilization, not just capacity: The majority of recent expansions have focused on removing bottlenecks and reusing byproducts rather than pure capacity addition; the new block enables recovery and reuse that was previously impossible.
- Underutilization costs are a near-term margin drag: Dahej carries significant expenses for employees and utilities that are underutilized because markets were previously weak; as occupancy increases and the new block goes commercial, margins should improve since operational costs for the new block are largely already covered.
- Existing plant can reach ₹850-900 crore in revenue: At current pricing levels, the existing plant capacity supports this revenue target within 2.5 to 3 years; the Jolva greenfield project will add completely different products not possible at the Dahej site.
New Business Verticals
- Semiconductor gets its first plant-scale order: The company received its first plant-scale production order from a customer for three batches at ton scale, 3 metric tons each; all previous approvals were at pilot scale, marking a critical step toward commercial validation.
- Full semiconductor commercialization targeted for 2028: The ramp-up will be gradual, and management describes it as a "big opportunity" if the current trajectory continues, though it is still too early to size the opportunity precisely.
- New agro product ready for scale-up: A new agro product developed over several years using novel technology has been approved by multiple customers at pilot scale and is ready for commercialization; management sees no reason not to scale up given consistent pilot results and customer approvals.
- SDA demand driven by Euro 7 norms: The company is already commercially selling products that go into Euro 7 converters; the transition from Euro 6 to Euro 7 requires larger catalyst quantities, not just a demand surge, and global adoption is expected to grow from 2027 to 2030 across the US, China, and India.
- Two new SDA customers onboarded: One is in the final stages of signing a contract, with commercial supplies expected to start around August.
Chintan Shah: "It is something very new in terms of technology. And surprisingly, it has been working very consistently up to the pilot, and the samples have been approved, material has been put to use by customers -- number of customers. And things look fine. So now there is no rhyme and reason why we should not go and scale up this opportunity."
Jolva Greenfield Project
- Groundbreaking imminent: Preparatory work is progressing with high readiness, and the company expects to break ground during the current quarter, around mid-February, with formal announcements at the appropriate stage.
- Commissioning targeted for September-October 2027: The plant will enhance operational flexibility and scalability, with commercialization expected over the following 18 months.
- Jolva serves a different purpose from Dahej: The plant will house a completely new set of agro products and expansion of current existing products; the capex largely goes toward new products that cannot be made at the Dahej site.
Segment Outlook & Growth Levers
- Agro intermediate demand seen as stable for 2026: The calendar year is expected to be similar to 2025, with a turnaround beginning gradually in 2027.
- Pharma commercialization consolidates from Q2 FY27: Until then, demand is likely to be intermittent as customer validation and ramp-up continue; commercialization will begin in the second half of calendar year 2026.
- New intermediates to contribute meaningfully by CY27-28: Six intermediates, three agro and three pharma, are expected to generate INR200-250 crore in revenue in calendar year 2027, with pharma intermediates alone contributing INR150 crore from calendar year 2028.
- SDA segment growth pegged at 25-30%: Driven by Euro 7 adoption, which will continue to grow for the next four years as it moves globally.
- Market recovery narrative points to H2 2027: Management notes that the second half of 2027 is when industry participants feel things will start to change, though geopolitical factors are impacting globally.
Chintan Shah: "The thing, which probably differentiates my views from the rest of the industry is because we had absolutely nearly no presence in this sector, let us say, a year or two years back. So whatever development that we have brought into this segment has come with lot of innovative technologies. So we have kept ourselves largely away from conventional chemistry and focused largely on catalytic or electrolytic chemistries."
Margins & Financial Expectations
- EBITDA margin target of 20-22% is realistic: Management expects FY27 should see this level, supported by the new block removing cost bottlenecks and improving operating leverage.
- New product margins are attractive: Gross profit margins for new products are similar to SDA, with nearly zero waste, providing a favorable mix shift as these products scale.
- ROCE debate remains unresolved: An analyst asserted that even at 80-90% utilization, ROCE would at most reach 10-12%; management disagreed, arguing that the conventional process and continuous flow parts of the plant will also impact ROCE, and it will not remain at 7% or 10% for the next financial year.
- Asset turn guidance was declined: Management declined to give a specific number for asset turn expectations from the Dahej plant, noting the plant serves multiple purposes including addressing bottlenecks, making it difficult to isolate returns from one particular investment.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Dahej new block commercial production | Commercial production to begin | First week of March 2026 |
| Jolva greenfield groundbreaking | Break ground at Jolva, Dahej | Current quarter (Q4 FY26), around mid-February |
| Jolva plant commissioning | Commissioning and commercial use | September or October 2027 |
| FY26 revenue growth | 20% to 30% YoY growth "definitely achievable" | FY26 |
| FY27 revenue growth | Similar to FY26, with potential for larger growth if Jolva is commissioned | FY27 |
| Overall revenue from existing plant | INR850-900 crore at current pricing levels | Within 2.5 to 3 years |
| EBITDA margin | 20% to 22% realistically achievable | FY27 |
| SDA segment growth | 25% to 30% growth | Ongoing |
| New intermediates revenue | INR200-250 crore from six intermediates (3 agro, 3 pharma) | Calendar year 2027 |
| Pharma intermediate revenue | INR150 crore | Calendar year 2028 |
| Semiconductor full commercialization | Gradual ramp-up to full commercialization | Around 2028 |
| New SDA customer commercial supplies | Commercial supplies to begin | Around August 2026 |
| Pharma commercialization consolidation | Demand to consolidate after intermittent validation phase | Q2 FY27 |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue (Pharma & Agro Intermediates and Specialty Chemicals) | ₹47.1 cr, 45% sequential growth and 86% YoY increase |
| Revenue (Structured Directing Agents) | ₹53.4 cr, 10% decline QoQ and 65% YoY growth |
| SDA 9-month revenue | ₹150 cr |
| Overall revenue target | ₹850 cr to ₹900 cr, achievable in 2.5 to 3 years at current pricing levels |
| FY26 YoY growth guidance | 20% to 30% |
| FY27 YoY growth guidance | Similar to FY26 |
| EBITDA margin target | 20% to 22%, realistically achievable; FY27 expected to reach this range |
| ROCE | ~7% currently |
| SDA capacity utilization | ~50% currently, had been as low as 35%, now roughly 55% |
| SDA segment growth expectation | 25% to 30% |
| Electrolyte Salts revenue contribution expectation | 7% to 8% of revenue in calendar year 2026, up from ~1% currently |
| New agro and pharma intermediates revenue target | ₹200 cr to ₹250 cr in calendar year 2027 |
| New product revenue target | ₹150 cr in calendar year 2028 |
| Dahej new block capex | ~₹100 cr (final number pending, roughly ₹102 cr range) |
| Jolva greenfield phase 1 capex | ₹265 cr to ₹270 cr (final amount pending) |
| Jolva plant commissioning timeline | September or October 2027 |
| Semiconductor full-scale commercialization | Expected around 2028 |